Der Nervenarzt

, 82:1385 | Cite as

Die Zukunft der Biomarker in der Demenzdiagnostik

Leitthema
First Online:

Zusammenfassung

Die neurochemische Demenzdiagnostik (NDD) ist ein Routineinstrument in der Diagnostik neurodegenerativer Erkrankungen wie der Alzheimer-Erkrankung (Alzheimer’s disease, AD). Gegenwärtig werden zwei Biomarkergruppen verwendet, die im Liquor cerebrospinalis („cerebrospinal fluid“, CSF) gemessen werden. Es handelt sich um Amyloid-β-Peptide (Aβ) und Tau-Proteine einschließlich hyperphosphorylierte Formen (pTau). Aktuell geht die Entwicklung der NDD in folgende Richtungen: 1. Suche nach neuen Biomarkern mit verbesserter diagnostischer Leistung; 2. Suche nach Biomarkern im Blut; 3. Anwendung neuer Technologien zur ökonomischeren Handhabung der Patientenproben; 4. Optimierung der Bestimmung bereits verwendeter Biomarker (z. B. durch verbesserte Qualitätskontrolle und Vergleichbarkeit der Ergebnisse unterschiedlicher Labore). In diesem Artikel geben wir einen kurzen Überblick über die gegenwärtige Situation auf dem Gebiet der liquorbasierten NDD und fassen einige Hypothesen zur möglichen zukünftigen Entwicklung zusammen.

Schlüsselwörter

Alzheimer-Erkrankung Liquor cerebrospinalis Amyloid β Tau-Protein Klinische Neurochemie 

The future of biomarkers in dementia diagnostics

Summary

Neurochemical dementia diagnostics (NDD) is a routine laboratory tool in the diagnostic process of patients with neurodegenerative disorders, such as Alzheimer’s disease (AD). Currently, two groups of biomarkers analyzed in the cerebrospinal fluid (CSF) are being considered, namely amyloid β (Aβ) peptides and tau proteins, along with the hyperphosphorylated forms of the latter (p-tau). Current directions in the development of NDD include the following: 1. search for novel biomarkers with improved analytical or diagnostic performance; 2. search for biomarkers in the blood; 3. applications of novel technologies enabling better management of patient samples; 4. optimization of the analysis of the biomarkers already available (for example, by improved quality control and inter-laboratory comparison of results). This review presents the state of the art in the field of CSF-based NDD and also summarizes some of the hypotheses of how the future development of NDD tools might look.

Keywords

Alzheimer disease Cerebrospinal fluid Amyloid β Tau proteine Clinical neurochemistry 
This is a preview of subscription content, log in to check access.

Notes

Interessenkonflikte

Der korrespondierende Autor weist auf folgende Beziehungen hin: PL ist Fachberater für Innogenetics. Die anderen Autoren geben an, dass kein Interessenkonflikt bestehe.

Literatur

  1. 1.
    Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:270–279PubMedCrossRefGoogle Scholar
  2. 2.
    Andreasen N, Blennow K (2005) CSF biomarkers for mild cognitive impairment and early Alzheimer’s disease. Clin Neurol Neurosurg 107:165–173PubMedCrossRefGoogle Scholar
  3. 3.
    Andreasen N, Sjogren M, Blennow K (2003) CSF markers for Alzheimer’s disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry 4:147–155PubMedCrossRefGoogle Scholar
  4. 4.
    Barthel H, Gertz HJ, Dresel S et al (2011) Cerebral amyloid-beta PET with florbetaben (18 F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 10:424–435PubMedCrossRefGoogle Scholar
  5. 5.
    Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx 1:213–225PubMedCrossRefGoogle Scholar
  6. 6.
    Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2:605–613PubMedCrossRefGoogle Scholar
  7. 7.
    Carson RT, Vignali DA (1999) Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J Immunol Methods 227:41–52PubMedCrossRefGoogle Scholar
  8. 8.
    DeMattos RB, Bales KR, Cummins DJ et al (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 98:8850–8855PubMedCrossRefGoogle Scholar
  9. 9.
    DeMattos RB, Bales KR, Cummins DJ et al (2002) Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease. Science 295:2264–2267PubMedCrossRefGoogle Scholar
  10. 10.
    Di Luca M, Pastorino L, Bianchetti A et al (1998) Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. Arch Neurol 55:1195–1200CrossRefGoogle Scholar
  11. 11.
    Dubois B, Feldman HH, Jacova C et al (2010) Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 9:1118–1127PubMedCrossRefGoogle Scholar
  12. 12.
    Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746PubMedCrossRefGoogle Scholar
  13. 13.
    Felgenhauer K, Beuche W (1999) Labordiagnostik neurologischer Erkrankungen: Liquoranalytik und -zytologie, Diagnose- und Prozessmarker. Thieme, StuttgartGoogle Scholar
  14. 14.
    Funke SA, Birkmann E, Henke F et al (2007) Single particle detection of Abeta aggregates associated with Alzheimer’s disease. Biochem Biophys Res Commun 364:902–907PubMedCrossRefGoogle Scholar
  15. 15.
    Gabelle A, Roche S, Geny C et al (2010) Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40, and 42 in human cerebrospinal fluid. Brain Res 1357:175–183PubMedCrossRefGoogle Scholar
  16. 16.
    Graff-Radford NR, Crook JE, Lucas J et al (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64:354–362PubMedCrossRefGoogle Scholar
  17. 17.
    Hampel H, Buerger K, Zinkowski R et al (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 61:95–102PubMedCrossRefGoogle Scholar
  18. 18.
    Kuo YM, Kokjohn TA, Watson MD et al (2000) Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am J Pathol 156:797–805PubMedCrossRefGoogle Scholar
  19. 19.
    Lewczuk P, Beck G, Ganslandt O et al (2006) International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 409:1–4PubMedCrossRefGoogle Scholar
  20. 20.
    Lewczuk P, Esselmann H, Bibl M et al (2004) Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer’s disease: original data and review of the literature. J Mol Neurosci 23:115–122PubMedCrossRefGoogle Scholar
  21. 21.
    Lewczuk P, Esselmann H, Otto M et al (2004) Neurochemical diagnosis of Alzheimer’s dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging 25:273–281PubMedCrossRefGoogle Scholar
  22. 22.
    Lewczuk P, Kamrowski-Kruck H, Peters O et al (2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer’s disease: a multicenter study. Mol Psychiatry 15:138–145PubMedCrossRefGoogle Scholar
  23. 23.
    Lewczuk P, Kornhuber J, Vanderstichele H et al (2008) Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging 29:812–818PubMedCrossRefGoogle Scholar
  24. 24.
    Lewczuk P, Kornhuber J, Vanmechelen E et al (2010) Amyloid beta peptides in plasma in early diagnosis of Alzheimer’s disease: A multicenter study with multiplexing. Exp Neurol 223:366–370PubMedCrossRefGoogle Scholar
  25. 25.
    Mattsson N, Blennow K, Zetterberg H (2009) CSF biomarkers: pinpointing Alzheimer pathogenesis. Ann N Y Acad Sci 1180:28–35PubMedCrossRefGoogle Scholar
  26. 26.
    Mattsson N, Blennow K, Zetterberg H (2010) Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer’s disease: united we stand, divided we fall. Clin Chem Lab Med 48:603–607PubMedCrossRefGoogle Scholar
  27. 27.
    Mayeux R, Honig LS, Tang MX et al (2003) Plasma A[beta]40 and A[beta]42 and Alzheimer’s disease: relation to age, mortality, and risk. Neurology 61:1185–1190PubMedGoogle Scholar
  28. 28.
    McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269PubMedCrossRefGoogle Scholar
  29. 29.
    Olsson A, Vanderstichele H, Andreasen N et al (2005) Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51:336–345PubMedCrossRefGoogle Scholar
  30. 30.
    Preston SD, Steart PV, Wilkinson A et al (2003) Capillary and arterial cerebral amyloid angiopathy in Alzheimer’s disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol Appl Neurobiol 29:106–117PubMedCrossRefGoogle Scholar
  31. 31.
    Reiber H (2001) Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 310:173–186PubMedCrossRefGoogle Scholar
  32. 32.
    Riemenschneider M, Schmolke M, Lautenschlager N et al (2000) Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer’s disease: association with apolipoprotein E genotype and cognitive decline. Neurosci Lett 284:85–88PubMedCrossRefGoogle Scholar
  33. 33.
    Sperling RA, Aisen PS, Beckett LA et al (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:280–292PubMedCrossRefGoogle Scholar
  34. 34.
    Sun X, Steffens DC, Au R et al (2008) Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry 65:542–550PubMedCrossRefGoogle Scholar
  35. 35.
    Oijen M van, Hofman A, Soares HD et al (2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5:655–660PubMedCrossRefGoogle Scholar
  36. 36.
    Verwey NA, Flier WM van der, Blennow K et al (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. Ann Clin Biochem 46:235–240PubMedCrossRefGoogle Scholar
  37. 37.
    Vignali DA (2000) Multiplexed particle-based flow cytometric assays. J Immunol Methods 243:243–255PubMedCrossRefGoogle Scholar
  38. 38.
    Wiltfang J, Esselmann H, Maler JM et al (2001) Molecular biology of Alzheimer’s dementia and its clinical relevance to early diagnosis and new therapeutic strategies. Gerontology 47:65–71PubMedCrossRefGoogle Scholar
  39. 39.
    Zetterberg H, Wahlund LO, Blennow K (2003) Cerebrospinal fluid markers for prediction of Alzheimer’s disease. Neurosci Lett 352:67–69PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Psychiatrische und Psychotherapeutische KlinikUniversitätsklinikum ErlangenErlangenDeutschland

Personalised recommendations